HR-8205-119
Placed on the Union Calendar, Calendar No. 637.
Sponsored by Mike Quigley (D-IL)
What it does
This bill would extend the Accelerating Access to Critical Therapies for ALS Act — originally set to expire in 2026 — through fiscal year 2031. It would also add new requirements for grant renewals (including review of enrollment, safety, and efficacy data), require grantees to promptly report unexpected serious adverse events from phase 3 trials, clarify that combined phase 2/3 clinical trials qualify under the program, and direct the FDA to publish a rare neurodegenerative disease action plan within 18 months and a follow-up progress report within 5 years.
Who benefits
ALS patients and their families, who would continue to benefit from federally funded research into treatments and cures. Researchers and academic institutions receiving NIH and FDA grants for ALS and other rare neurodegenerative disease studies. Biotechnology and pharmaceutical companies developing ALS therapies, who gain continued access to grant funding and a clearer regulatory pathway. Patients with other rare neurodegenerative diseases (e.g., frontotemporal dementia, primary lateral sclerosis) who may benefit from the broadened FDA action plan. Clinical trial participants, who gain additional safety reporting protections.
Who is hurt
Grant applicants whose renewal applications may face additional scrutiny due to new data review requirements, potentially slowing funding decisions. Competing research priorities — other disease areas may face indirect resource competition if ALS-specific programs absorb a larger share of FDA and NIH capacity. Taxpayers bear the cost of the extended program, though the specific appropriated amount is not specified in the bill text. Small biotechnology firms may face increased administrative burden from the new adverse event reporting requirements.
Supporters argue
Supporters argue that ALS remains a uniformly fatal disease with no cure and very limited treatment options, affecting roughly 30,000 Americans at any given time, and that the original 2021 Act created a proven framework for accelerating research that should not be allowed to lapse. They contend that the new safety reporting and data review requirements strengthen accountability for federal grant dollars, and that expanding the FDA action plan to cover rare neurodegenerative diseases more broadly maximizes the program's public health return by addressing related conditions that share research infrastructure and scientific challenges.
Opponents argue
Opponents argue that reauthorizing the program for five additional years without specifying funding levels or requiring a rigorous independent evaluation of the original Act's outcomes fails to ensure taxpayer dollars are being spent effectively. They contend that the new FDA action plan mandate adds regulatory reporting obligations without clear enforcement mechanisms or measurable benchmarks, and that Congress should conduct a thorough cost-benefit review of the 2021 program's results before committing to an extended run rather than treating reauthorization as a routine procedural step.